Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Staufen1 RNA-binding protein drives prostate cancer development

Key clinical point: The RNA-binding protein Staufen1 was increased in multiple lines of human prostate cancer cells.

Major finding: Staufen1 has a direct impact on prostate cancer development in several ways; knockdown of Staufen1 was associated with significantly decreased cell motility and cell invasion levels in PC3 and DU145, and with lower proliferative capacity for LNCaP.

Study details: The data come from an evaluation of three independent prostate cancer cell lines, PC3, DU145 and LNCaP cells, that are often used to identify the underlying disease mechanisms in prostate cancer patients.

Disclosures: The study was supported in part by operating grants from the Canadian Institutes of Health Research, the Cancer Research Society, and the University of Ottawa, Faculty of Medicine. The researchers had no financial conflicts to disclose.


Marcellus KA et al. BMC Cancer. 2021 Feb 4. doi: 10.1186/s12885-021-07844-2.